Australia TGA ARTG recordCryoLab - Cryogenic spray, cutaneous
Australia TGA ARTG Registered Device · Emergo Asia Pacific Pty Ltd T/a Emergo Australia · CryoConcepts LP · Class IIa · Started December 12, 2021
Good Name: Emergo Asia Pacific Pty Ltd T/a Emergo Australia - CryoLab - Cryogenic spray, cutaneous
- Risk Class
- Class IIa
- Product Type
- Medical device system
- ARTG Category
- General
- Start Date
- December 12, 2021
- Effective Date
- December 12, 2021
- Name
- CryoConcepts LP
- Country
- United States of America
- Address
- 1100 Conroy Place, Easton, PA, 18040
This device is intended for the surgical destruction of target tissue by applying cryogenic gases at extreme low temperatures. Below are examples of the types of lesions that can be treated: Molluscum Contagiosum Skin Tags Actinic Keratosis Lentigo Verruca Plana Verruca Vulgaris Verruca Plantaris Genital Lesions Seborrheic Keratosis
Access comprehensive regulatory information for CryoLab - Cryogenic spray, cutaneous in the Australia medical device market through Pure Global AI's free TGA ARTG database. This Class IIa is sponsored by Emergo Asia Pacific Pty Ltd T/a Emergo Australia, manufactured by CryoConcepts LP in United States of America. The device registration started on December 12, 2021.
This page provides complete registration details including sponsor information, manufacturer details, and regulatory compliance data from the official Australia TGA ARTG medical device database. Pure Global AI offers free access to Australia's complete medical device registry with 131,000+ devices, helping global MedTech companies navigate TGA regulations efficiently.